


p27 Polyclonal Antibody

Catalog No :	YT3501
Reactivity :	Human;Rat;Mouse;Bovine
Applications :	WB;IHC;IF;ELISA
Target :	p27
Fields :	>>Endocrine resistance;>>ErbB signaling pathway;>>HIF-1 signaling pathway;>>FoxO signaling pathway;>>Cell cycle;>>PI3K-Akt signaling pathway;>>AGE-RAGE signaling pathway in diabetic complications;>>Cushing syndrome;>>Measles;>>Human papillomavirus infection;>>Epstein-Barr virus infection;>>Pathways in cancer;>>Transcriptional misregulation in cancer;>>Viral carcinogenesis;>>MicroRNAs in cancer;>>Prostate cancer;>>Chronic myeloid leukemia;>>Small cell lung cancer;>>Gastric cancer
Gene Name :	CDKN1B
Protein Name :	Cyclin-dependent kinase inhibitor 1B
Human Gene Id :	1027
Human Swiss Prot No :	P46527
Mouse Swiss Prot No :	P46414
Immunogen :	The antiserum was produced against synthesized peptide derived from human p27 Kip1. AA range:149-198
Specificity :	p27 Polyclonal Antibody detects endogenous levels of p27 protein.
Formulation :	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Source :	Polyclonal, Rabbit,IgG
Dilution :	WB 1:500-2000, ELISA 1:10000-20000 IHC 1:50-300. IF 1:50-200
Purification :	The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.


Concentration :	1 mg/ml
Storage Stability :	-15°C to -25°C/1 year(Do not lower than -25°C)
Observed Band :	27kD
Cell Pathway :	ErbB_HER;Cell_Cycle_G1S;Cell_Cycle_G2M_DNA;Pathways in cancer;Prostate cancer;Chronic myeloid leukemia;Small cell lung cancer;
Background :	This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Mutations in this gene are associated with multiple endocrine neoplasia type IV (MEN4). [provided by RefSeq, Apr 2014],
Function :	disease:Defects in CDKN1B are the cause of multiple endocrine neoplasia type 4 (MEN4) [MIM:610755]. Multiple endocrine neoplasia (MEN) syndromes are inherited cancer syndromes of the thyroid. MEN4 is a MEN-like syndrome with a phenotypic overlap of both MEN1 and MEN2.,domain:A peptide sequence containing only AA 28-79 retains substantial Kip1 cyclin A/CDK2 inhibitory activity.,function:Important regulator of cell cycle progression. Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Positive regulator of cyclin D-dependent kinases such as CDK4. Regulated by phosphorylation and degradation events.,induction:Maximal levels in quiescence cells and early G(1). Levels decrease after mitogen stimulation as cells progress toward S-phase.,miscellaneous:Decreased levels of p27Kip1, mainly due to proteosomal degradation, are found in various epithelial tumors originating
Subcellular Location :	Nucleus. Cytoplasm. Endosome . Nuclear and cytoplasmic in quiescent cells. AKT- or RSK-mediated phosphorylation on Thr-198, binds 14-3-3, translocates to the cytoplasm and promotes cell cycle progression. Mitogen-activated UHMK1 phosphorylation on Ser-10 also results in translocation to the cytoplasm and cell cycle progression. Phosphorylation on Ser-10 facilitates nuclear export. Translocates to the nucleus on phosphorylation of Tyr-88 and Tyr-89. Colocalizes at the endosome with SNX6; this leads to lysosomal degradation (By similarity). .
Expression :	Expressed in kidney (at protein level) (PubMed:15509543). Expressed in all tissues tested (PubMed:8033212). Highest levels in skeletal muscle, lowest in liver and kidney (PubMed:8033212).
Tag :	orthogonal
Sort :	1126

No4 :	1
Host :	Rabbit
Modifications :	Unmodified

Products Images




Han, Wei, et al. "ZIC1 acts a tumor suppressor in breast cancer by targeting survivin." *International journal of oncology* 53.3 (2018): 937-948.




Immunohistochemical analysis of paraffin-embedded Human-liver-cancer tissue. 1, p27 Polyclonal Antibody was diluted at 1:200 (4°C, overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C, 20min). 3, Secondary antibody was diluted at 1:200 (room temperature, 30min). Negative control was used by secondary antibody only.




Immunohistochemical analysis of paraffin-embedded Human-kidney-cancer tissue. 1, p27 Polyclonal Antibody was diluted at 1:200 (4°C, overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C, 20min). 3, Secondary antibody was diluted at 1:200 (room temperature, 30min). Negative control was used by secondary antibody only.



Western Blot analysis of various cells using p27 Polyclonal Antibody diluted at 1:500



Western Blot analysis of COLO205 cells using p27 Polyclonal Antibody diluted at 1:500



Western blot analysis of lysates from HeLa, HepG2, and COLO205 cells, using p27 Kip1 Antibody. The lane on the right is blocked with the synthesized peptide.